<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562883</url>
  </required_header>
  <id_info>
    <org_study_id>13/20/DD-BVMD</org_study_id>
    <nct_id>NCT04562883</nct_id>
  </id_info>
  <brief_title>Single vs. Group CAPA-IVM Culture of Cumulus-oocyte Complexes</brief_title>
  <official_title>Effect of Single vs. Group CAPA-IVM Culture of Human Cumulus-oocyte Complexes From Small Antral Follicles in a SIBLING Oocyte Study Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mỹ Đức Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mỹ Đức Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oocyte in vitro maturation (IVM) is a minimal-stimulation ART with reduced hormone-related&#xD;
      side effects and risks for the patients. However, the approach is not widely used because of&#xD;
      an efficiency gap compared to conventional ART. In order to further optimize and adapt the&#xD;
      CAPA-IVM system in the IVM clinic, this pilot study aims to check the feasibility of applying&#xD;
      a single COC CAPA-IVM strategy versus the group COC culture CAPA-IVM&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oocyte in vitro maturation (IVM) is a minimal-stimulation ART with reduced hormone-related&#xD;
      side effects and risks for the patients. However, the approach is not widely used because of&#xD;
      an efficiency gap compared to conventional ART.&#xD;
&#xD;
      Oocytes retrieved for IVM procedures derive from a heterogeneous pool with variable cellular&#xD;
      and molecular characteristics that indicate its immature status. Thus, in vitro systems that&#xD;
      permit and enhance acquisition and synchronization of meiotic competence (ability to resume&#xD;
      meiosis in response to an ovulatory stimulus) and developmental competence (ability to be&#xD;
      fertilized and support early embryo development) before the meiotic trigger are crucial for&#xD;
      the optimization of human IVM systems.&#xD;
&#xD;
      A novel two-step IVM culture system (named CAPA-IVM) involving a pre-maturation culture with&#xD;
      C-type natriuretic peptide (CNP) and a maturation step in presence of Amphiregulin (AREG),&#xD;
      both more physiological compounds improving oocyte competence, have been introduced in&#xD;
      previous clinical studies. So far these pilot studies proved to increase the rates of oocyte&#xD;
      maturation, good quality embryos on day 3, good quality blastocyst, and as a result a higher&#xD;
      embryo yield. CAPA-IVM blastocysts have shown similar rates of methylation and gene&#xD;
      expression at gDMRs compared to COS embryos; and the expression of ma-jor epigenetic&#xD;
      regulators was similar between both groups. Furthermore, an improvement in pregnancy rates&#xD;
      strengthens the clinical relevance of the use of CAPA-IVM strategy.&#xD;
&#xD;
      In order to further optimize and adapt the CAPA-IVM system in the IVM clinic, this pilot&#xD;
      study aims to check the feasibility of applying a single COC CAPA-IVM strategy versus the&#xD;
      group COC culture CAPA-IVM. A single COC culture would permit to perform a non-invasive&#xD;
      molecular analysis per matured oocyte, in order to identify quality genes ex-pressed in&#xD;
      cumulus cells post-IVM (cumulus biomarkers), which could be subsequently used to identify the&#xD;
      embryo(s) with highest potential of implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of good quality embryos</measure>
    <time_frame>At least 3 days after intra-cytoplasmic sperm injection</time_frame>
    <description>Number of good quality Day 3 embryos obtained</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maturation rate</measure>
    <time_frame>Two days after oocytes pick-up</time_frame>
    <description>Percentage of mature oocytes by 2 types of COC culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>16-18 hours after intra-cytoplasmic sperm injection</time_frame>
    <description>Percentage of fertilized oocytes by 2 types of COC culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cleavage rate</measure>
    <time_frame>At least 3 days after intra-cytoplasmic sperm injection</time_frame>
    <description>Percentage of day-3 embryos over fertilized oocytes by 2 types of COC culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion rate</measure>
    <time_frame>After at least 30 hours of maturation culture</time_frame>
    <description>Percentage of cumulus-oocyte complexes expanded after culture by 2 types of COC culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relative expression ratio ( R ) of human cumulus cell genes</measure>
    <time_frame>cumulus cells will be collected after at least 30 hours of maturation culture, storaged at -80oC until RNA purification</time_frame>
    <description>Cumulus cells will be collected, cDNA synthesis after mRNA purification, relative quantification PCR for detecting gene expression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>IVF</condition>
  <condition>PCOS</condition>
  <condition>IVM</condition>
  <arm_group>
    <arm_group_label>Single Culture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfer the COCs cultured individually in Capacitation medium to the individual washing droplets from the &quot;washing dish&quot; containing &quot;Maturation Medium&quot; and wash them thoroughly. Then transfer COCs one by one to the &quot;Culture dish&quot; with &quot;Maturation Medium&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Culture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfer half of the COCs (5-10 at a time) from the Capacitation culture dish to the &quot;washing dish&quot; containing &quot;Maturation Medium (Group Culture)&quot; by using an Eppendorf micropipette and wash them thoroughly (load pipette tips with 5µl, max. 10µl). Then transfer COCs to the &quot;IVM dish&quot; with &quot;Maturation Medium (Group Culture)&quot;.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The way of Cumulus-oocyte complexes (COC) culture</intervention_name>
    <description>Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.</description>
    <arm_group_label>Group Culture</arm_group_label>
    <arm_group_label>Single Culture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having polycystic ovarian morphology: at least 25 follicles (2-9 mm) throughout the&#xD;
             whole ovary and/or increased ovarian volume (&gt;10ml) (it is sufficient that 1 ovary&#xD;
             fits these criteria)&#xD;
&#xD;
          -  No major uterine or ovarian abnormalities&#xD;
&#xD;
          -  Having at least 15 follicles on the OPU day&#xD;
&#xD;
          -  Patients consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High (&gt;grade 2) grade endometriosis&#xD;
&#xD;
          -  Cases with extremely poor sperm (serve OAT: density &lt;1 million, mobility &lt;10% and&#xD;
             sperm from testicular surgery)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuong M Ho, MD, MCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>My Duc Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Sanchez F, Le AH, Ho VNA, Romero S, Van Ranst H, De Vos M, Gilchrist RB, Ho TM, Vuong LN, Smitz J. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. J Assist Reprod Genet. 2019 Oct;36(10):2135-2144. doi: 10.1007/s10815-019-01551-5. Epub 2019 Aug 9.</citation>
    <PMID>31399916</PMID>
  </reference>
  <reference>
    <citation>Vuong LN, Le AH, Ho VNA, Pham TD, Sanchez F, Romero S, De Vos M, Ho TM, Gilchrist RB, Smitz J. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. J Assist Reprod Genet. 2020 Feb;37(2):347-357. doi: 10.1007/s10815-019-01677-6. Epub 2020 Jan 4.</citation>
    <PMID>31902102</PMID>
  </reference>
  <reference>
    <citation>Sánchez F, Romero S, De Vos M, Verheyen G, Smitz J. Human cumulus-enclosed germinal vesicle oocytes from early antral follicles reveal heterogeneous cellular and molecular features associated with in vitro maturation capacity. Hum Reprod. 2015 Jun;30(6):1396-409. doi: 10.1093/humrep/dev083. Epub 2015 Apr 22.</citation>
    <PMID>25904637</PMID>
  </reference>
  <reference>
    <citation>Saenz-de-Juano MD, Ivanova E, Billooye K, Herta AC, Smitz J, Kelsey G, Anckaert E. Genome-wide assessment of DNA methylation in mouse oocytes reveals effects associated with in vitro growth, superovulation, and sexual maturity. Clin Epigenetics. 2019 Dec 19;11(1):197. doi: 10.1186/s13148-019-0794-y. Erratum in: Clin Epigenetics. 2020 Jan 27;12(1):18.</citation>
    <PMID>31856890</PMID>
  </reference>
  <results_reference>
    <citation>Sánchez F, Lolicato F, Romero S, De Vos M, Van Ranst H, Verheyen G, Anckaert E, Smitz JEJ. An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield. Hum Reprod. 2017 Oct 1;32(10):2056-2068. doi: 10.1093/humrep/dex262.</citation>
    <PMID>28938744</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 5, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAPA-IVM</keyword>
  <keyword>Single culture</keyword>
  <keyword>Group culture</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

